Design Therapeutics to Present Data on Friedreich's Ataxia Trial
Design Therapeutics is set to announce crucial data from its Phase 1/2 trial of DT-216P2 for Friedreich's ataxia on May 18, 2026. This event is significant for investors as successful outcomes could enhance its valuation and market position in the biotechnology sector.
View signal analysis